Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Conditions

Prostate

Phase III

What is the purpose of this trial?

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

  • Ages
    18 years and older
  • Gender
    Male only
  • Trial with
    NRG Oncology
  • Start Date
    05/14/2018
  • End Date
    04/29/2021
Trial Image

For more information about this study, contact:

Jennifer Pope

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    07/31/2018
  • Study HIC
    #2000022286